Bio-gene Technology Ltd. · ASX:BGT
Bio-gene Technology — Shareholder Meeting (November 2024)
13 slides from Bio-gene Technology's shareholder meeting presentation, Nov 29, 2024
Slide 1: Annual General Meeting FY2024 Presentation
Bio-Gene Technology Limited | ASX: BGT For personal use only Annual General Meeting Developing new insecticides derived from nature to achieve high impact worldwide. FY2024 Presentation Tim Grogan Managing Director & CEO www.bio-gene.com.au www.bio-gene.com.au 1
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an
Slide 3: Contents
Contents For personal use only Company Highlights 04. Product Overview 05. Commercial Strategy 06. Milestones & News Flow 14. www.bio-gene.com.au www.bio-gene.com.au 3
Slide 4: Company Highlights
Company Highlights Focused development of two new insecticides with strong commercial validation. 01. Two New Actives For personal use only Late-stage development: two insecticidal compounds derived from nature with novel modes of action: » Flavocide® and Qcide® are derived from a unique sub-type of
Slide 5: Our Unique Products Derived from Nature
Our Unique Products Derived from Nature For personal use only Qcide® Qcide is an 100% natural oil extracted from the leaves of a specific cultivar of eucalypt (Gypmie messmate) currently farmed in northern Australia. ✓ 12th harvest in QLD completed in 2024 Flavocide® Flavocide is based on flavesone,
Slide 6: Flavocide & Qcide - Multiple Market Segments
Flavocide & Qcide - Multiple Market Segments Bio-Gene is targeting five large well-developed global markets For personal use only Sectors Crop Protection Grain Storage Public Health Consumer Applications Animal Health Urban Pest Management, Vector Control for Malaria, Livestock & Pet-care Food & Fib
Slide 7: Flavocide & Qcide – Our Pipeline
Flavocide & Qcide – Our Pipeline Bio-Gene is targeting five large well-developed global markets For personal use only Active constituent Description Sectors Target uses Partners & Collaborators 1 Grain Protectant Crop protection Admixture to grain 2 Outdoor Space Spray Public health Flying insects F
Slide 8: Flavocide Development Path
Flavocide Development Path Regulatory approval of a formulated product is a two-step process. For personal use only Commercial Partner Agreements Launch Regulatory Development (market) Manufacturing process improvements and scale-up #1. Flavocide AI: data and regulatory dossier 1st dossier evaluatio
Slide 9: FY24 & Recent Achievements
FY24 & Recent Achievements For personal use only 8 August 2024 14 August 2024 2 September 2024 Study plans for Flavocide on track Envu collaboration to evaluate Flavocide Flavocide production successful at following APVMA feedback for mosquito management pre-commercial scale www.bio-gene.com.au www.
Slide 10: Bio-Gene's Strategic Priorities
Bio-Gene’s Strategic Priorities Strategy is focused on efficient development and approval of Flavocide and Qcide, with more commercial partnerships. For personal use only Speed Efficient Use of Capital Particularly the pre-registration To leverage the funding from manufacturing and safety shareholde
Slide 11: Key Forward Milestones & News Flow
Key Forward Milestones & News Flow Bio-Gene has many catalysts to drive value over the next 18 months, with a strong pipeline of near-term news flow. For personal use only 01 02 03 Flavocide & Qcide development Partnering & commercial Funding & other support ✓ Flavocide regulatory studies ✓ New comm
Slide 12: Questions?
Questions? For personal use only Contact Tim Grogan Managing Director & CEO timg@bio-gene.com.au Matthew Wright NWR Communications matt@nwrcommunications.com.au 0451 896 420 www.bio-gene.com.au www.bio-gene.com.au 12
Slide 13: Proxy Summary Report as at 27-Nov-24
Proxy Summary Report as at 27-Nov-24 50,000,000 45,000,000 For personal use only 40,000,000 35,000,000 Axis Title 30,000,000 25,000,000 20,000,000 15,000,000 10,000,000 5,000,000 0 ASX Listing Rule 7.1A Enable the issue of Approval to Re-election of Mr. Peter (additional issuance equity securities u
Bio-Gene Technology — Shareholder Meeting (November 2024) on 6ix